AnaptysBio Inc., a biotech developing antibody products for inflammation and cancer, announced the appointment of James A. Schoeneck to its board of directors.
Schoeneck is president and CEO of Depomed, a specialty pharma recently valued at $1 billion that mainly markets pain pills and products for diseases of the central nervous system.
Prior to joining Depomed in 2011, Schoeneck was CEO of BrainCells Inc., ActivX BioSciences and Prometheus Laboratories Inc., according to a recent news release. Before Prometheus, Schoeneck led the development of Centocor's commercial development, including the market launch of therapeutic antibody, Remicade.
“Jim brings a strong track-record in building biotechnology companies and commercialization of therapeutic products,” said AnaptysBio CEO and President Hamza Suria, in a statement. “His experience is highly relevant for AnaptysBio's strategic vision to advance our anti-IL-33 antibody program to multiple clinical proof-of-concept studies and develop our anti-IL-36 receptor antibody to market launch in orphan inflammatory conditions."